Skip to main content

Table 2 Baseline comorbidities and concomitant medications for patients with HCV genotype 1b treated with elbasvir/grazoprevir

From: Effectiveness of Elbasvir/Grazoprevir in US Veterans with Chronic Hepatitis C Virus Genotype 1b Infection

 Total population
N = 3614
Anxiety, n (%)1039 (28.8)
Hypertension, n (%)2687 (74.4)
Cirrhosis, n (%)920 (25.5)
Depression, n (%)1984 (54.9)
Hepatocellular carcinoma, n (%)47 (1.3)
Diabetes, n (%)1408 (39.0)
History of drug use, n (%)1691 (46.8)
History of alcohol use, n (%)2033 (56.3)
HCV/HIV co-infection, n (%)56 (1.6)
History of kidney transplant, n (%)39 (1.1)
History of liver transplant, n (%)12 (0.3)
eGFR stage, n (%)
 eGFR ≥ 60 mL/min/1.73 m22661 (73.6)
 Stage 3a537 (14.9)
 Stage 4/5b325 (9.0)
Concomitant PPI, n (%)1021 (28.3)
  1. eGFR estimated glomerular filtration rate, HCV hepatitis C virus, HIV human immunodeficiency virus, PPI proton pump inhibitor
  2. aeGFR ≥ 30 to < 60 mL/min/1.73 m2
  3. beGFR ≤ 29 mL/min/1.73 m2
Back to article page